The two companies will work with the Environmental Molecular Science Laboratory, a U.S. Department of Energy user facility located at PNNL, and will leverage Cellenion’s flagship platform for single cell isolation and nanoliter dispensing
Today, SCIENION and Cellenion, drivers of BICO, a leading bio convergence company, announced that they have exclusively licensed a PNNL invention and have also entered into a research and development collaboration agreement with EMSL. Through this trans-Atlantic partnership, researchers in France, Germany and the U.S. will further develop the Nanodroplet Processing in One pot for Trace Samples (nanoPOTS) platform towards commercial use.
“We are very excited to finally make nanoPOTS a commercially available product,” said Dr. Anjali Seth, Single Cell Proteomics Project Leader at Cellenion. “This agreement is another key milestone for taking single cell sample preparation and analysis to the next level.”
The nanoPOTS technology was developed by PNNL scientists specifically to address sample processing for mass-spectrometry based small sample analysis. In combination with cellenONE®, Cellenion’s unique technology for single cell isolation and ultra-small volume dispensing, the nanoPOTS platform enables ultrasensitive liquid chromatography-mass spectrometry analysis to provide in-depth proteomics analyses of biological samples as small as single cells.
“The analytic power provided by nanoPOTS could help identify new sources of clean energy, unlock secrets to keeping agriculture healthy during droughts, and pinpoint disease markers for diabetes and cancer,” said Jennifer Lee, PNNL’s market commercialization manager. “As a national laboratory, one of our core missions is to transfer the intellectual property developed through federal funding to private industry where they can make a positive societal impact. We look forward to nanoPOTS being accessible to the broader scientific community.”
The agreement further strengthens Cellenion’s position in the field of sample preparation for single cell analysis in genomics and proteomics.
BICO Press office
Riley Munks, PR Manager (650) 863-6699
Alyssa D’Orazio, PR Manager (617) 634-960
Email: [email protected]
Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is a complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Dortmund and Berlin, and has subsidiaries in Arizona, USA; Chichester, UK; and Cellenion in Lyon, France.
SCIENION is part of BICO, the leading bio convergence company in the world that provides technologies, products and services to create, understand and master biology.
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell isolation. Cellenion has developed cellenONE®, a unique technology allowing high-throughput, image-based automated sorting and dispensing of cells onto any substrate. Together with a range of dedicated consumables, cellenONE enables miniaturization of sample preparation protocols. With no dead volumes and outstanding recovery rates, Cellenion’s platform offers unique capacities for applications including single cell transcriptomics, genomics, proteomics, rare cells and cell line development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on the Nasdaq the Stockholm under BICO. www.bico.com